Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5190591 plus Pegasys and Copegus versus Pegasys and Copegus in treatment-naive genotype 1 chronic hepatitis C
2009-009608-38Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of danoprevir in hepatitis C virus infection (2 arms), sponsored by Roche. Primary endpoint: Sustained virologic response. Started Jun 2009; status: completed.
02
Drugs
danoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-009608-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009608-38.